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INTRODUCTION 
Gastro-oesophageal reflux disease (GORD) is responsible for some of the most frequently 
reported symptoms in both primary and secondary care: between 20-30% of adults in 
developed countries experience reflux symptoms intermittently1-3.  Diagnosis is usually based 
on related symptoms, such as “heartburn”, acid regurgitation and dysphagia.  The major 
objectives of treatment are control of symptoms, with reduction in the frequency and duration 
of reflux and pain, and improvement in health related quality of life (HRQOL).   
 
GORD and its management represent a significant health care cost.   The yearly budget within 
the British National Health Service for PPIs is £300million4,5, approximately 30% of which is 
for treatment of oesophagitis and reflux symptoms.  The majority of patients with significant 
GORD remain on long-term treatment.   
 
Medical treatment for GORD depends on the severity of symptoms; thus it often escalates 
from self-administered antacids through lifestyle changes to the intermittent use of acid 
suppression therapy followed by continuous use of H2 receptor agonists (H2RAs) or more 
commonly proton pump inhibitors (PPIs).  Whilst PPIs are usually highly effective and are 
generally assumed to be safe, there are concerns about the long-term use of acid suppression 
treatments.  Patients with persistent GORD uncontrolled by PPIs, or who do not wish long-
term medical treatment, may be offered surgery.   
 
Surgical treatment for GORD takes the form of fundoplication, in which the upper part of the 
stomach (fundus) is wrapped around the lower oesophagus, and may be performed either as a 
minimal access (laparoscopic) or an open procedure.  Although fundoplication is effective in 
controlling GORD it is unclear whether the benefits in controlling GORD outweigh the 
potential risks and side effects of the surgery6, 7.   
 
The REFLUX (Randomised Evaluation oF Laparoscopic sUrgery for refluX) trial is a large 
multicentre trial, funded by the NHS R&D Health Technology Assessment Programme, 
which aims to compare the clinical and cost effectiveness of minimal access surgery with best 
medical treatment for patients with GORD, for whom both treatments are acceptable options.   
As the diagnosis and management of GORD is largely based on patient reporting of 
symptoms, the primary outcome measure in the trial is patient-reported HRQOL.     
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Although several GORD-specific or gastro-intestinal-specific symptom scales and quality of 
life scales have been developed8-16, none captures the experience of patients receiving 
alternative treatments in sufficient detail for evaluating outcomes in the REFLUX trial.  Of 
particular concern was that these measures do not reflect patients’ experience of the side 
effects of surgery for GORD, which include general gastro-intestinal symptoms as well as 
reflux itself14.  A new condition-specific outcome measure was therefore developed for use 
within the trial.  The aim of this measure was not only to assess the symptoms of GORD, but 
also the side effects of both medical and surgical treatment for GORD, and the effect these 
have on HRQOL.  There were three requirements for the new measure: it had to measure 
health-related quality of life not merely symptom experience; its content had to cover the 
effects of treatment for GORD as well as the symptoms of GORD; and it had to summarise 
data in a form suitable for economic evaluation.  This paper reports on the development and 
assessment of the new measure.   
 
 
 
METHOD 
Questionnaire development 
Between May and September 2000, a series of one to one interviews and focus groups were 
carried out with patients in two cities, Leeds and Aberdeen, in order to identify those themes 
and issues related to GORD and its treatment that were important to them.  Thirty-one people 
were interviewed, 15 receiving medical treatment, and 16 who had received surgery.  In 
addition, two focus groups were conducted, each with six patients, one in Aberdeen and one 
in Leeds.  Both focus groups included only patients who had received surgery for their GORD 
symptoms, identified via their gastroenterologist or surgeon. 
   
Both the interviews and focus groups followed the same general format.  Patients were asked 
questions about the types and severity of the symptoms they experienced, how best to 
describe their symptoms, whether they felt their symptoms were best described by their 
frequency, duration and level of distress, and about the impact their symptoms had on their 
daily lives.     
 
All interviews and focus groups were audio taped and transcribed.  These transcripts 
underwent thematic analysis by three members of the trial team.  Emerging themes and issues 
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suggested potential questionnaire items.  Wherever possible the language used by patients was 
used when devising the items.  The transcripts showed frequency and effect of symptoms on 
patients’ quality of life were the two most common themes.  
 
Piloting  
The initial version of the questionnaire (31 items) was piloted on a sample of 21 patients from 
Aberdeen, some of whom had taken part in the interview phase.  The questionnaires were 
posted out to the patients asking them to complete it.  At a later date they were interviewed 
about its readability and acceptability. Specifically, they were questioned about whether they 
had problems understanding the items, whether the response categories were appropriate for 
them, and whether they thought anything was missing from the questionnaire.  The 
questionnaire was modified following the feedback from these interviews.  A small number of 
items (n=3) were discarded as unsuitable or potentially ambiguous, others were re-worded and 
3 items that were not originally included in the initial version of the questionnaire, but were 
repeatedly mentioned by the patients and felt to be of importance, were added.   
 
Final questionnaire  
The 31 items that were included in the formally evaluated version of the questionnaire were 
grouped into 7 categories (Heartburn; Acid reflux; Wind; Eating and swallowing; Bowel 
movements; Sleep; and Work, physical and social activities) describing symptoms relating to 
GORD or side effects of treatment (table 1).  For each category respondents were asked to 
show how often they had experienced problems with specified symptoms over the past two 
weeks, followed by how much they felt those symptoms had affected their quality of life, also 
over the past two weeks.  The symptom items offered five responses from “not at all” to 
“every day” while the quality of life items offered five responses – “not at all”, “a little”, 
“moderately”, “a lot” and “extremely”.  Items in the less clinical category ‘Work, physical 
and social activities’ offered six responses, including “not applicable” (Appendix).   
 
Table 1 about here 
 
Data 
The new measure, along with two generic measures of HRQOL (EQ-5D17 and SF-3618) and 
information on background, demographics and use of medicine, was included in a postal 
questionnaire, which was sent to all REFLUX trial participants.  Trial participants were sent a 
questionnaire at baseline after they have agreed to take part in the trial, at first follow-up (3 
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months after surgery or its equivalent for non surgical participants) and at second follow-up 
(12 months after surgery or equivalent).  This paper reports on data received by December 
2004, when 794 participants had returned a questionnaire at baseline, 602 participants had 
returned a questionnaire at first follow-up, and 418 participants had returned a questionnaire 
at second follow-up.  Most of the analysis presented here was performed on the baseline data, 
but analysis of sensitivity to change also used the first follow-up data. 
  
Analysis  
Developing a scoring system 
We planned that the new measure would produce two different types of score: 
- a Reflux quality of life score (RQLS) summarising the extent to which respondents’ 
symptoms affect their quality of life, where 0 is the worst quality of life and 100 is the best; 
and 
- a series of seven Reflux symptom scores which profile respondents’ experience these 
categories groups of symptoms over the past two weeks.    
 
While it is possible to generate summary scores by merely summing the raw scores on each 
item, this assumes that all items in the measure are equally important.  It disregards the 
possibility that some items are more important than others and should therefore have a larger 
effect on the final score.  So we have used two distinct methods of weighting items’ 
contribution to total score.   
 
The Reflux questionnaire contains seven quality of life items, each relating to one of its seven 
categories, that require participants to indicate how much they feel their symptoms on a 
particular dimension in the past two weeks have affected their general quality of life.  Weights 
for the RQLS were estimated by assessing the influence of these items on participants’ 
assessment of their general quality of life.  We used the seven baseline quality of life items as 
independent variables in an ordinary least squares (OLS) regression model with participants’ 
assessment of their general HRQOL, as measured by the EQ-5D visual analogue scale (EQ-
5D VAS), as dependent variable.  For modelling purposes we assumed that the data from 
these items were cardinal.  EQ-5D VAS requires respondents to assess their current state of 
health on a 0-100 visual analogue scale, where 0 represents worst imaginable health and 100 
best imaginable health.  To remain in the model, regression coefficients did not have to be 
statistically significant but they did have to have the correct (negative) sign, i.e. a reported 
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detrimental effect on quality of life should be associated with a decrease in EQ-5D VAS 
score.  The resulting coefficients were used as weighting factors to calculate a general quality 
of life summary score.   
 
In contrast weights for the Reflux symptom summary scores were generated by entering the 
31 baseline symptom items into a principal components analysis (PCA) with a Varimax 
rotation.  We judged how many components or factors to extract by using a combination of 
the Kaiser criterion (include all factors with an eigenvalue greater than 1) and a ‘scree plot’ of 
those eigenvalues.  The resulting factor loadings were used as the item weights to calculate a 
number of symptom scores.   
 
Reliability, validity and sensitivity to change 
We assessed the reliability of the Reflux quality of life and symptom scores by internal 
consistency, as measured by Cronbach’s alpha.  In contrast our assessment of the validity and 
responsiveness or sensitivity to change of the new measure concentrated on the quality of life 
score, as this was the main aim of the measure. The validity of the RQLS was assessed by 
comparing its performance against the SF-36.  Sensitivity to change was assessed by the 
measure’s ability to reflect changes in participants’ condition, as assessed by self-reported 
change in prescribed medication between baseline and first follow-up.  Participants were 
asked to give details of their prescribed medication use (PPIs, H2RAs and anti-emetics) at 
baseline and at first follow-up.  This information was used to classify whether their 
medication use had changed between these times or not.   
 
 
 
RESULTS 
Sample characteristics  
Between March 2001 and June 2004 a total of 810 participants had been recruited into the 
REFLUX trial, of whom 799 had completed and returned their baseline questionnaires.  By 
December 2004 602 participants out of 649 (93%) had returned a first follow-up 
questionnaire, and 418 out of 447 (94%) a second follow-up questionnaire.  At baseline, 64% 
of the sample was male and the median age at trial entry was 46 years (range 18 to 74).   
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Scoring 
Generating weights for the Reflux quality of life score (RQLS).   
All 727 participants with complete baseline data on the Reflux quality of life items and EQ-
5D VAS were included in the analysis.  Though coefficients for three of the seven quality of 
life items were not statistically significant, we kept them in the regression model for 
completeness.  In contrast we excluded the Wind item from the RQLS model as the 
coefficient consistently showed the wrong sign and was not statistically significant.  In effect 
the Wind item will receive a weight of zero when calculating the final score.  The Work, 
physical and social activities item had the largest coefficient and thus had most effect on the 
EQ-5D VAS,, and the Sleep item the smallest coefficient.   The final model is in table 2. 
 
Table 2 about here 
 
The coefficients from this model were used as weights for calculating the quality of life score 
by multiplying the response to each quality of life item (coded from 0 “not at all” to 4 
“extremely”) by the corresponding weight (i.e. the coefficient from table 2) and subtracting 
these values from the constant term in the following model: 
 
a) Raw RQLS = 90-(heartburn quality of life x 1.35) - (acid reflux quality of life x 1.70) - 
(wind quality of life x 0) - (eating quality of life x 1.10) - (bowel movement quality of life x 
1.95) - (sleep quality of life x 0.35) - (activities quality of life x 2.15). 
 
The score was then standardised to a scale from 0 (worst quality of life) to 100 (best quality of 
life) as follows: 
 
b) Standardised RQLS = (Raw RQLS - 55.6) x 2.91 
 
Figure 1 presents the frequency distribution of quality of life scores for patients at baseline.  
The mean score was 65.0 with a standard deviation of 24.3.   
 
Figure 1 about here 
 
Generating weights for the Reflux symptom scores  
PCA identified five components that accounted for 57% of the variance in the items (table 3).  
In general the component structure reflected the themes identified when the items were 
developed.  However Component 1 grouped together heartburn-like symptoms and sleep 
disruption into something like general discomfort (table 3).  The first component after rotation 
explained 19% of the total variance and included seven items with loadings above 0.4.  
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Component 2 explained 12% of the total variance and included six main items.  The 
remaining 3 components accounted respectively for 10%, 9% and 8% of the total variance.  
Component loadings were used to construct a profile of five Reflux symptom scores to 
summarise an individual’s symptom experience.  In the first instance we suggest the 
following labels for these components: 1 = general discomfort; 2 = wind & frequency; 3 = 
nausea & vomiting; 4 = activity limitation; and 5 = constipation & swallowing. 
 
Table 3 about here 
 
Each symptom score was calculated by multiplying the response to each of the symptom 
items in that score (coded from 0 “every day” to 4 “not at all”) by the corresponding weight 
(i.e. the coefficient from table 3) and then summing across the items.  For the four items in 
activity limitation we grouped the response codes “not applicable” and “no my symptoms do 
not affect me” as 4, and recoded the other categories from 3 “my symptoms have affected me 
but I still work/perform these activities” to 0 “I no longer work/perform these activities 
because of my symptoms”.  Symptom scores were then standardised to a scale from 0 (worst 
symptom score) to 100 (best symptom score) as follows:  
 
General discomfort = 5.24 x ((item A1 x 0.674) + (item A2 x 0.643) + (item B1 x 0.654) + 
(item D2 x 0.421) + (item F1 x 0.777) + (item F2 x 0.814) + (item F3 x 0.791)) . 
 
Wind & frequency = 6.59 x ((item C1 x 0.738) + (item C2 x 0.553) + (item C3 x 0.568) + (item 
C4 x 0.515) + (item E1 x 0.722) + (item E3 x 0.696))  
 
Nausea & vomiting = 9.84 x ((item B2 x 0.734)+(item B3 x 0.556)+(item B4 x 0.541) + (item 
B5 x 0.709))  
 
Activity limitation = 9.58 x ((item G1 x 0.695) + (item G2 x 0.571)+(item G3 x 0.755) + (item 
G4 x 0.588))  
 
Constipation & swallowing = 13.72 x ((item D1 x 0.338) + (item E2 x 0.839) + (item E4 x 
0.645))  
 
Table 4 presents the mean symptom scores at baseline.  There were pronounced ceiling effects 
for nausea & vomiting, constipation & swallowing, and activity limitations: 26%, 25% and 
17% respectively of the sample had a maximum score of 100.    In contrast wind & frequency 
showed a more normal distribution. 
 
Table 4 about here 
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Both the RQLS and Reflux symptom scores were calculated only for individuals with 
complete data.  However there were few missing data.  Reflux scores could be calculated for 
over 95% of patients at baseline.  Missing data rates for symptom items ranged between 1 and 
2% and for quality of life items between 3 and 5%. 
 
Reliability 
The reliability coefficient (Cronbach’s alpha) measuring the internal consistency of the RQLS 
was 0.90.  For the Reflux symptom scores alphas were: general discomfort 0.87; wind & 
frequency 0.78; nausea & vomiting 0.75; activity limitations 0.68; and constipation & 
swallowing 0.56.  Apart from the last item, all alphas are greater than 0.7, which is generally 
considered satisfactory19.   
 
Validity 
Table 5 presents the relationship (Pearson’s r) between the RQLS and the eight SF-36 
dimension scores.  Social functioning and bodily pain showed the best relationship with the 
RQLS, and the mental health dimension the worst.   
 
Table 5 about here 
 
Table 6 presents the proportion of respondents who had a score of 100 (best health) on the SF-
36 dimensions as a percentage of those who had a best score of 100 on the RQLS.  While 
96% of those who had the maximum score on the SF-36 physical functioning dimension also 
had a score of 100 on the RQLS, only 31% of those who had a score of 100 on the SF-36 
bodily pain dimension also had a score of 100 on the RQLS.   
 
Table 6 about here 
 
Figure 2 plots the mean RQLS against the SF-36 physical component score (PCS) and mental 
component score (MCS) grouped into fifths.  The mean RQLS increases steadily and 
significantly between successive PCS groups.  There is a similar pattern for MCS groups 
except that respondents in the highest fifth have a lower mean RQLS than those in the next 
lower fifth.  
 
Figure 2 about here 
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Sensitivity to change 
Participants reported whether they were being prescribed medication at baseline and first 
follow-up.  This information was used to classify them into four groups: those prescribed 
medication at baseline and follow-up (N=293); those prescribed medication at baseline but 
not follow-up (N=186); those who prescribed medication at follow-up but not baseline (N=3); 
and those not prescribed medication at all (N=7).  As the last groups are reassuringly small, 
Figure 3 presents mean change in RQLS (baseline score - follow-up score) for the first two 
groups 
 
Figure 3 about here 
 
A negative score indicates an improvement in quality of life.  Although the RQLS improved 
for both groups (paired t-tests showed significant change), patients whose medication status 
changed between baseline and follow-up (medication at baseline but not at follow-up) showed 
a greater improvement in their RQLS than patients whose medication status stayed the same 
(medication at baseline and follow-up).    
 
 
 
DISCUSSION 
Principal findings 
This paper describes a new outcome measure for use with patients with gastro-oesophageal 
reflux disease (GORD).  The Reflux questionnaire comprises 31 items and generates a single 
score (RQLS) measuring the extent to which individual participants feel that their GORD 
symptoms, and any side effects of treatment, affect their quality of life.  The 31 items also 
generate five Reflux symptom scores measuring the extent to which those participants 
experienced clusters of symptoms over the past two weeks.  Thus the RQLS provides a single 
index that can be used to record change for evaluation, while the symptom scores provide a 
descriptive profile that describes whether respondents experience problems in specific 
clusters.  The data presented provide evidence that the new measure is valid, reliable and 
sensitive to change.    
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Strengths of the study 
The Reflux questionnaire was designed as a patient-centred self-completed postal 
questionnaire.  Items were generated by using GORD patients as key informants, rather than 
relying on the views of clinicians or other experts.  So the Reflux questionnaire covers those 
elements of their illness that GORD patients indicated were important in determining their 
quality of life.  A patient-centred approach also underlies the scoring system used to generate 
the RQLS.  The weights used to create this score were based on the relationship between 
participants’ reports of their scores on seven quality of life items and of their general health 
status on a visual analogue scale.  The score takes account of patients’ preferences through 
their self-reported effect on quality of life.  In contrast the Reflux symptom scores, not 
intended as measures of HRQOL, used essentially statistical weights, generated from 
principal components analysis of symptom frequencies rather than patients’ views.   
 
The performance of a measure may also be assessed by its acceptability to respondents.  
Although the Reflux questionnaire has 31 items, it suffered very few reported difficulties or 
missing item responses within the REFLUX trial.  During the pilot modifications were based 
on patient feedback on the acceptability and readability of items.   
 
Weaknesses of the study 
The most common method of establishing the validity of a measure is to analyse its 
association with a criterion of known validity that is accepted as a ‘gold standard’.  However 
there is no gold standard for quality of life in, or disease severity in, GORD by which to 
determine validity14.  Nevertheless the REFLUX trial does use SF-36 and EQ-5D, two 
reputable measures of generic HRQOL, though not designed for use with GORD patients.  As 
we had used the EQ-5D VAS to generate the RQLS, we used the SF-36 to establish construct 
validity.  The RQLS showed good correlations with the SF-36 dimensions of bodily pain and 
social functioning, topics common to both measures, and weaker correlations with mental 
health and energy, topics not included in the Reflux questionnaire.  Though we used self-
reported change in medication to assess the sensitivity of the RQLS to change, this assumes 
that changing from being prescribed medication to not being prescribed medication 
necessarily shows improved health status.  
 
The second issue in establishing the validity of the Reflux questionnaire is that the analysis 
was based on patients with controlled symptoms, since one of the trial inclusion criteria was 
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“reasonable symptom control” with medication.  Thus 10% of patients achieved the best 
possible RQLS at baseline, showing that their GORD was affecting quality of life “not at all”, 
probably because medication provided complete symptom control.  There is scope to 
ameliorate these ceiling effects in future.   
 
The final issue relates to the interpretability of the five Reflux symptom scores, derived 
through multivariate statistical analysis.  To interpret the resulting weights we have suggested 
five labels: general discomfort; wind & frequency; nausea & vomiting; activity limitation; and 
constipation & swallowing.  Though the first four are easy to interpret, the fifth contains only 
three items – “difficulty in swallowing” and two relating to constipation.  Although these 
appear heterogeneous, that is a common consequence of multivariate analysis, which takes 
full account of correlations between items.  Furthermore these items play little part in the 
other four dimensions, and have been identified as potential side effects of surgical treatment.  
We have therefore retained this fifth dimension, more to assess changes after treatment rather 
than status at baseline. 
 
Unanswered questions 
The aim of this paper was to validate a new measure of the HRQOL of patients being treated 
for GORD.  Further evidence about the performance of the measure will be available through 
detailed analysis of the REFLUX trial, due to be completed in 2006.  Although our principal 
aim was to develop and validate an outcome measure for use in the REFLUX trial, we hope 
that the Reflux questionnaire will prove more widely applicable.   
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Figure 1.  Distribution of RQLS 
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Figure 2.  RQLS by SF-36 physical component summary score and mental component 
summary score (grouped in fifths) 
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Figure 3. Change in RQLS by change in prescribed medication (baseline to follow-up)  
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Table 1.  Reflux categories 
Category Number of items 
Heartburn 3 
Acid reflux 6 
Wind 5 
Eating and swallowing 3 
Bowel movements 5 
Sleep 4 
Work, physical and social activities 5 
 
 
Table 2.  Model coefficients used to calculate the Reflux Quality of Life Score (RQLS) 
Reflux quality of life item Β SE Sig 
Heartburn -1.346 0.81 NS 
Acid reflux -1.700 0.70 <0.05 
Eating and swallowing -1.103 0.68 NS 
Bowel movements -1.954 0.61 <0.01 
Sleep -0.351 0.66 NS 
Work, physical and social activities -2.147 0.84 <0.05 
Constant 89.995 1.51 <0.001 
Adj R2=0.22 
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Table 3.  Component loadings used to calculate the Reflux symptom scores 
Item  Component 
1 
Component 
2 
Component 
3 
Component 
4 
Component 
5 
A1: heartburn 0.674     
A2: discomfort in chest 0.643     
B1: acid reflux 0.654     
B2: vomiting   0.734   
B3: regurgitating   0.556   
B4: nausea   0.541   
B5: urge to be sick   0.709   
C1: flatulence  0.738    
C2: belching  0.553    
C3: feeling bloated  0.568    
C4: stomach gurgling  0.515    
D1: difficulty swallowing     0.338 
D2: eating restricted 0.421     
E1: diarrhoea  0.722    
E2: constipation     0.839 
E3: urgent need to go  0.696    
E4: feeling like bowels not 
emptied 
    0.645 
F1: difficulty sleeping 
lying down 
0.777     
F2: difficulty getting to 
sleep 
0.814     
F3: disrupted sleep 0.791     
G1: paid/unpaid work    0.695  
G2: less strenuous 
activities 
   0.571  
G3: strenuous activities    0.755  
G4: social activities    0.588  
Note: Factor loadings <0.3 have been suppressed. 
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Table 4.  Mean Reflux symptom scores at baseline   
Reflux symptom dimension Mean  SD Median 
General discomfort 59.4 25.6 60.3 
Wind & frequency I 50.7 22.1 49.6 
Nausea & vomiting 81.7 19.6 89.0 
Activity limitation 79.2 16.5 81.5 
Constipation & swallowing 77.7 20.6 79.6 
 
 
 
Table 5.  Relationship (Pearson’s r) between RQLS and SF-36 dimension scores  
SF-36 dimension RQLS  
Physical functioning 0.42 
Role limitations-physical 0.49 
Bodily pain 0.56 
General health perception 0.46 
Energy/vitality 0.34 
Social functioning 0.59 
Role limitations-emotional 0.41 
Mental health 0.18 
 
 
 
Table 6.  Percentage (n) of respondents with maximum RQLS with maximum score on 
the SF-36 dimensions 
 
SF-36 dimension % (n)
Physical functioning 96 (70) 
Role limitations-physical 66 (48) 
Bodily pain 31 (23) 
General health perception -- 
Energy/vitality -- 
Social functioning 74 (54) 
Role limitations-emotional 97 (71) 
Mental health -- 
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Appendix 
 
 
 
 
 
 
 
 
 
 
 
The Reflux 
Questionnaire 
 
 
 
 
 
 
REFLUX QUESTIONNAIRE 
 
For the following questions, please put a cross in the box which best describes how often 
your symptoms have occurred and the effect they have had on your quality of life. 
 
SECTION A  -  HEARTBURN 
 
 
 
A1. In the last two weeks, how often have you experienced heartburn (a burning 
sensation which moves up from your chest to your throat)? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
  
A2. In the last two weeks, how often have you experienced any discomfort or pain in 
your chest? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
  
A3. In the last two weeks, how much has the heartburn or discomfort/pain in your chest 
affected your quality of life? 
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely  
 
SECTION B - ACID REFLUX 
 
 
 
B1. In the last two weeks, how often have you experienced acid reflux and/or had an 
acid taste in your mouth? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Every day 
  
B2. In the last two weeks, how often have you been sick (vomited)? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
  
 
B3. In the last two weeks, how often have you regurgitated (brought up) quantities of 
liquid or solids into your mouth? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
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B4. In the last two weeks, how often have you experienced a feeling of nausea (without 
 actually being sick or regurgitating)? 
 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
  
 
B5. In the last two weeks, how often have you wanted to be sick but physically been 
unable to? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
  
 
B6. In the last two weeks, how much have these reflux symptoms affected your quality 
of life? 
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely  
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 SECTION C – WIND 
 
 
 
C1. In the last two weeks, how often have you experienced a lot of wind from the lower 
bowel? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day  
 
 
C2. In the last two weeks, how often have you experienced a lot of burping/belching? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day  
  
 
C3. In the last two weeks, how often have you experienced bloatedness and/or a 
feeling of trapped wind, in your stomach? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
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C4.  In the last two weeks, how often have you experienced loud gurgling noises from 
your stomach?    
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
  
 
C5. In the last two weeks, how much have these wind problems affected your quality of 
life? 
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely  
 
 
 
SECTION D - EATING AND SWALLOWING 
 
 
 
D1. In the last two weeks, how often have you experienced difficulty swallowing food or 
have you actually choked on food? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
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D2. In the last two weeks, how often have your eating habits been restricted because of 
your condition?  Examples might be eating more slowly, having smaller portions or 
eating different foods. 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
  
 
D3. In the last two weeks, how much have these problems with eating affected your 
quality of life?   
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely 
 
 
 
 
SECTION E – BOWEL MOVEMENTS 
   
E1. In the last two weeks, how often have you experienced diarrhoea and/or loose 
stools? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
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 E2. In the last two weeks, how often have you experienced constipation and/or hard 
stools? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
  
 
E3. In the last two weeks, how often have you felt an urgent need to have a bowel 
movement ?       
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
  
 
 
E4. In the last two weeks, how often have you had a feeling of not emptying your 
bowels? 
 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Every day 
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 E5. In the last two weeks, how much have these bowel problems affected your quality 
of life? 
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely 
 
 
SECTION F – SLEEP 
 
 
 
F1. In the last two weeks, how often have you experienced difficulty in lying down to 
sleep? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most nights 
 Every night 
  
 
 
F2. In the last two weeks, how often have you experienced difficulty getting to sleep 
because of your reflux symptoms? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most nights 
 Every night 
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F3. In the last two weeks, how often have you been woken up because of your reflux 
symptoms? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most nights 
 Every night 
  
 
F4. In the last two weeks, how much have these sleep related problems affected your 
quality of life?                
 
   
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely 
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 SECTION G – WORK, PHYSICAL AND SOCIAL ACTIVITIES 
 
 
For the following section, please put a cross in the box which best applies to you. 
 
 
G1. In the last two weeks, have your reflux symptoms affected you at work (paid or 
voluntary)? 
 
 Not applicable (I do not do paid or voluntary work) 
 No, my symptoms do not affect me 
 Yes, my symptoms have affected me but I still work 
 Yes, I have worked less often because of my symptoms 
 Yes, I have not worked in the last two weeks because of my symptoms 
I no longer work because of my symptoms 
  
 
G2. In the last two weeks, have your reflux symptoms affected your ability to perform 
less strenuous activities (such as going for a gentle walk, shopping or housework)? 
 
Not applicable (I do not perform these activities, 
though this is not due to my reflux symptoms) 
 No, my symptoms do not affect me 
 Yes, my symptoms have affected me but I still  
perform these activities as often as ever 
 Yes, I perform these activities less often because of my symptoms 
 Yes, I have not performed these activities in the last two weeks 
I no longer perform these activities at all because of my symptoms 
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 G3. In the last two weeks, have your reflux symptoms affected your ability to perform 
strenuous activities  (such as brisk walking or swimming)? 
 
Not applicable (I do not perform these activities, 
though this is not due to my reflux symptoms) 
 No, my symptoms do not affect me 
 Yes, my symptoms have affected me but I still  
perform these activities as often as ever 
 Yes, I perform these activities less often because of my symptoms 
 Yes, I have not performed these activities in the last two weeks 
I no longer perform these activities at all because of my symptoms 
 
G4. In the last two weeks, have you found that your reflux symptoms have affected any 
of your social activities (such as going out for meals, going out for drinks or 
socialising with other people)? 
 
Not applicable (I do not perform these activities,  
though this is not due to my reflux symptoms) 
 No, my symptoms do not affect me 
 Yes, my symptoms have affected me but I still  
perform these activities as often as ever 
 Yes, I perform these activities less often because of my symptoms 
 Yes, I have not performed these activities in the last two weeks 
I no longer perform these activities at all because of my symptoms 
 
 
 
G5. In the last two weeks, how much has the effect of your symptoms on your work, 
physical or social activities affected your quality of life? 
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely 
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